Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$314.77 USD

314.77
496,482

-1.73 (-0.55%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $315.11 +0.34 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

West Pharmaceutical (WST) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum on the back of a solid product portfolio and improving margins. However, forex woes linger.

    National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up

    by Zacks Equity Research

    Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.

    Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues

    by Zacks Equity Research

    Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.

    Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

    by Zacks Equity Research

    Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System.

    Haemonetics (HAE) Q1 Earnings Top Estimates, Margins Improve

    by Zacks Equity Research

    Ongoing recovery in businesses, especially Hospital, and the initial Plasma Persona rollouts drove Haemonetics (HAE) fiscal first-quarter revenues.

    Inari Medical (NARI) Q2 Earnings Lag, Revenues Top Estimates

    by Zacks Equity Research

    Inari Medical's (NARI) second-quarter 2021 results benefit from significant revenue growth and gross margin expansion.

    STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up

    by Zacks Equity Research

    STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.

    ShockWave Medical (SWAV) Q2 Earnings, Revenues Top Estimates

    by Zacks Equity Research

    ShockWave Medical's (SWAV) robust performance across product lines and geographies drive its Q2 sales.

    SmileDirectClub (SDC) Q2 Loss Wider Than Expected, Margin Up

    by Zacks Equity Research

    SmileDirectClub (SDC) registered year-over-year revenue growth in the second quarter, driven primarily by unique aligner shipment.

    Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up

    by Zacks Equity Research

    Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.

    Allscripts' (MDRX) Shares Up Following Q2 Earnings Beat

    by Zacks Equity Research

    Allscripts' (MDRX) robust Q2 results demonstrate its strength in Client services segment.

    Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top

    by Zacks Equity Research

    Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

    Glaukos (GKOS) Stock Gains 0.1% Following Lower Loss in Q2

    by Zacks Equity Research

    Despite reporting second-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

    AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Up

    by Zacks Equity Research

    AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.

    Nevro (NVRO) Q2 Earnings Surpass Estimates, Revenues Lag

    by Zacks Equity Research

    Nevro's (NVRO) worldwide revenues rise on a year-over-year basis in Q2 despite pandemic-led business challenges.

    Quidel (QDEL) Q2 Earnings Fall Shy of Estimates, Margins Down

    by Zacks Equity Research

    Quidel's (QDEL) dismal Q2 performance stems from lower revenues across majority of its product categories.

    Illumina (ILMN) Q2 Earnings Top Estimates, 2021 View Up

    by Zacks Equity Research

    Year-over-year improvement in segmental revenues in Q2 across all geographies exceeds Illumina's (ILMN) expectations.

    Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio

    by Zacks Equity Research

    Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.

      ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Down

      by Zacks Equity Research

      Increased demand for sleep devices and masks, including recovery of core sleep patient flow, drove ResMed's (RMD) fiscal fourth-quarter growth.

      Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat

      by Zacks Equity Research

      Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

        Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat

        by Zacks Equity Research

        Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.

        LHC Group (LHCG) Stock Loses 11.9% Despite Q2 Earnings Beat

        by Zacks Equity Research

        LHC Group's (LHCG) second-quarter results benefit from organic growth in both home health and hospice admissions.

        Is West Pharmaceutical (WST) a Solid Growth Stock? 3 Reasons to Think " Yes "

        by Zacks Equity Research

        West Pharmaceutical (WST) possesses solid growth attributes, which could help it handily outperform the market.

        Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up

        by Zacks Equity Research

        Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.